Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthmaopen access
- Authors
- Jung, Jae-Woo; Park, Hae-Sim; Park, Choon-Sik; Cho, Sang-Heon; Choi, Inseon S.; Moon, Hee-Bom; Kwon, Soon Seog; Yoon, Ho Joo; Park, Jung Won; Lee, Jong-Myung; Choi, Dong-Chull; Choi, Byoung Whui
- Issue Date
- Jul-2021
- Publisher
- 대한내과학회
- Keywords
- Omalizumab; Quality of life; Republic of Korea; Asthma; Prospective studies
- Citation
- The Korean Journal of Internal Medicine, v.36, no.4, pp 1001 - 1013
- Pages
- 13
- Journal Title
- The Korean Journal of Internal Medicine
- Volume
- 36
- Number
- 4
- Start Page
- 1001
- End Page
- 1013
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/18741
- DOI
- 10.3904/kjim.2020.549
- ISSN
- 1226-3303
2005-6648
- Abstract
- Background/Aims: Omalizumab is the first biologic known to be effective in patients with severe allergic asthma. Methods: This study was conducted as a multicenter, single-group, open trial to evaluate the improvement in the quality of life with the additional administration of omalizumab for 24 weeks in Korean patients with severe persistent allergic asthma. Results: Of the 44 patients, 31.8% were men and the mean age was 49.8 +/- 11.8 years. A score improvement of 0.5 points or more in the Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) was noted in 50.0% (22/44) of the patinets. In the improved group, the baseline total immunoglobulin E (IgE) level and the amount of omalizumab used were higher, and the day and night asthma symptoms were more severe, compared to those in the non-improved group. According to the Global Evaluation of Treatment Effectiveness, favorable outcomes were found in 78.6% of patients. The Korean asthma control test (p < 0.005) and forced expiratory volume in 1 second % predicted (FEV1%; p < 0.01) improved significantly in patients who received omalizumab treatment, compared to that at week o, and the total dose of rescue systemic corticosteroids significantly decreased (p < 0.05). The improved group on KAQLQ showed a significant improvement in FEV1% (p < 0.001). Conclusions: Omalizumab can be considered a biological treatment for Korean patients with severe allergic asthma. It is recommended to consider omalizumab as add-on therapy in patients with high baseline total IgE levels and severe asthma symptoms.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/18741)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.